• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Weekly Roundup: June 8-12

Article

ICYMI, we've curated a list of all the stories we've published throughout the past week. Check out this article for more Dermatology Times content.

In case you missed it, this week we featured stories involving lasers in acne treatment, reuse of N95 respirators, the efficacy of facial appearance apps, introduction of a teledermatology program in the U.S. Army two decades ago, as well as an exclusion webinar and a feature on being a dermatologist on the frontlines of COVID-19 in New York City, plus more.

Utility of lasers in acne treatment

The popularity of laser and light devices has recently grown among acne patients, not only due to their e­fficacy but also because treatments are quick and clean, says Michael H. Gold, M.D.

ASLMS gains new president and officers

The American Society for Laser Medicine and Surgery announces a new president and officers will be joining their Board of Directors for 2020-21.

COVID-19 considerations: Do state guidelines overrule the CDC?

In the COVID-19 era, standard of care is still evolving. David J. Goldberg, M.D., J.D., discusses this and more liability issues to consider when re-opening your practice.

Method allows reuse of N95 respirators during COVID-19

In part one of our video interview with Iltefat H. Hamzavi, M.D., he discusses how ultraviolet germicidal irradiation is used in dermatology and how it can be used to disinfect N95 respirators to facilitate reuse during the COVID-19 pandemic.

N95 respirator reuse possible with UVGI

In part two of our interview with Iltefat H. Hamzavi, M.D., he delves into the data from a recent article investigating the use ultraviolet germicidal irradiation (UVGI) as a method to disinfect N95 respirators for reuse during the COVID-19 pandemic.

Hairbrush helps calm down static

ForBabs introduces their X-Static hairbrush that keeps fly-aways and frizz at bay.

Do facial appearance apps work?

There seems to be an app for everything: losing weight, measuring hair loss, and facial appearance. The apps appear to be highly sophisticated and are very popular with consumers, but how do they work?

Dermatologists on New York City's COVID-19 frontlines

Eighteen residents and fellows in the throes of their dermatology training volunteered at the frontlines of overwhelmed Bronx-based hospitals during the height of the COVID-19 pandemic, gaining a crash course in crisis medicine and infectious diseases.

Telehealth: A tool for the moment or the new normal?

In this webinar, moderated by Daniel Siegel, M.D., M.A., FAAD, FACMS, experts discuss guidance on the use of teledermatology and ways to successfully implement new models of care during the COVID-19 pandemic.

Skin microbiota linked with systemic disease, rosacea

A recent paper discovered that the skin’s microbiota is closely associated with a number of systemic diseases, underscoring the need for clinicians to not only address the microbiota but also consider appropriate antibiotic therapy when contemplating treatment in rosacea patients.

Dermatologists recognized for contributions to teledermatology

AAD announces two physicians are recipients of the "Patient Care Hero" award for their work in implementing a teledermatology program in the U.S. Army program two decades ago.

Patient enrollment complete for tapinarof long-term safety study for psoriasis

Dermavant announces the enrollment completion for their long-term safety study investigating tapinarof in adults with plaque psoriasis as a part of the PSOARING 1 and PSOARING 2 phase 3 program.

EMA accepts marketing application for tralokinumab

LEO Pharma will soon begin marketing its monoclonal antibody tralokinumab for atopic dermatitis with the announcement that the EMA has accepted the marketing authorization application for the drug.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.